| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/19/2004 | WO2004014935A1 Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy |
| 02/19/2004 | WO2004014933A1 Compositions for rna interference and methods of use thereof |
| 02/19/2004 | WO2004014931A1 ARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME |
| 02/19/2004 | WO2004014930A1 PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-β-D- ALDOHEXOPYRANOSIDES |
| 02/19/2004 | WO2004014929A1 Derivatives of monosaccharides for drug discovery |
| 02/19/2004 | WO2004014927A1 Mitochondrially targeted antioxidants |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014919A1 Epothilone derivatives |
| 02/19/2004 | WO2004014917A2 Antitumoral analogs of lamellarins |
| 02/19/2004 | WO2004014915A1 Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
| 02/19/2004 | WO2004014913A2 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014910A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | WO2004014905A1 Substituted benzimidazole compounds |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014900A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| 02/19/2004 | WO2004014899A1 Thiophene compounds |
| 02/19/2004 | WO2004014897A1 N-aryl-2-oxazolidinones and their derivatives |
| 02/19/2004 | WO2004014896A1 Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
| 02/19/2004 | WO2004014894A1 Novel prodrugs of 1-methyl-2(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(n-2-pyridil-n-2-hydroxycarbonylethyl)-amide, production and use thereof as medicaments |
| 02/19/2004 | WO2004014893A2 Antimicrobial aza-bicyclic derivates, their compositions and uses |
| 02/19/2004 | WO2004014881A2 '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| 02/19/2004 | WO2004014880A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014875A1 Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide |
| 02/19/2004 | WO2004014859A2 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | WO2004014856A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/19/2004 | WO2004014852A2 Iminothiazolidinones as inhibitors of hcv replication |
| 02/19/2004 | WO2004014851A2 Tyrosine kinase inhibitors |
| 02/19/2004 | WO2004014849A2 Isosorbide mononitrate compositions and methods of their use |
| 02/19/2004 | WO2004014847A1 Mcp-1 receptor antagonists and method of use thereof |
| 02/19/2004 | WO2004014846A1 Modafinil polymorphic forms |
| 02/19/2004 | WO2004014844A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | WO2004014843A1 Substituted amino compounds and use thereof |
| 02/19/2004 | WO2004014842A1 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014835A2 Resolvins: biotemplates for therapeutic interventions |
| 02/19/2004 | WO2004014831A1 Polyisoprenylbenzophenone derivatives, method for production and use thereof |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014434A1 A method for monitoring the effectiveness of tetracycline in the treatment of asthma |
| 02/19/2004 | WO2004014432A1 Carrier |
| 02/19/2004 | WO2004014431A1 A parenteral dosage form of selective cox-2 inhibitors |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014429A1 Regulator for mental disease risk fragility |
| 02/19/2004 | WO2004014428A1 Remedy for intestinal diseases and visceral pain |
| 02/19/2004 | WO2004014427A1 Medicinal composition for lowering blood lipid level |
| 02/19/2004 | WO2004014426A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014413A1 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 02/19/2004 | WO2004014409A1 Developing method for separating d-amygdalin and neoamygdalin by reversed-phase hplc and optimum conditions for inhibition of racemization of amygdalin |
| 02/19/2004 | WO2004014405A1 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 02/19/2004 | WO2004014404A1 Echinacea angustifolia extracts |
| 02/19/2004 | WO2004014402A1 Activated carbon for preventing pregnancy and sexually transmitted disease |
| 02/19/2004 | WO2004014400A1 Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
| 02/19/2004 | WO2004014399A1 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 02/19/2004 | WO2004014398A1 The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection’s treatment and prevention |
| 02/19/2004 | WO2004014397A1 Analgetic cream comprising salicylate dispersed in silicone oil and microsponges for substained delivery of counter-irritants like menthol |
| 02/19/2004 | WO2004014396A1 Medicament comprising fluocinolone and dexamethasone and/or hydrocortisone and gentamicin and/or neomycin |
| 02/19/2004 | WO2004014395A1 Female hormone-containing patch |
| 02/19/2004 | WO2004014394A1 Antipruritic agent |
| 02/19/2004 | WO2004014393A1 Medicament and method for reducing alcohol and/or tobacco consumption |
| 02/19/2004 | WO2004014391A1 Use of carboxamides for the treatment of tinnitus |
| 02/19/2004 | WO2004014390A1 Novel pharmaceutical composition of ceftiofur |
| 02/19/2004 | WO2004014386A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 02/19/2004 | WO2004014385A1 Pharmacological treatment of psoriasis |
| 02/19/2004 | WO2004014383A1 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| 02/19/2004 | WO2004014382A1 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| 02/19/2004 | WO2004014380A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 02/19/2004 | WO2004014376A1 Gal3 receptor antagonists for the treatment of affective disorders |
| 02/19/2004 | WO2004014374A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | WO2004014373A1 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
| 02/19/2004 | WO2004014372A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014371A1 Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014368A1 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| 02/19/2004 | WO2004014367A2 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease |
| 02/19/2004 | WO2004014366A1 Hetero biaryl derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014362A1 Therapeutic process for the treatment of obesity and associated metabolic disorders |
| 02/19/2004 | WO2004014361A1 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity |
| 02/19/2004 | WO2004014360A2 Pharmaceutical compositions for the treatment of urinary incontinence |
| 02/19/2004 | WO2004014359A1 Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
| 02/19/2004 | WO2004014358A1 Methods of preventing headaches with norepinephrine precursors |
| 02/19/2004 | WO2004014357A2 Therapeutic use of aryl amino acid derivatives |
| 02/19/2004 | WO2004014356A1 Solid compositions comprising gabapentin having improved stability |
| 02/19/2004 | WO2004014355A1 A peritoneal dialysis solution comprising a pyruvate |
| 02/19/2004 | WO2004014353A1 Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014351A2 Use of cgrp antagonist compounds for treatment of psoriasis |
| 02/19/2004 | WO2004014349A1 New molecules for modulating drug resistance in fungus |
| 02/19/2004 | WO2004014346A1 Palatable controlled-release formulation for companion animals |
| 02/19/2004 | WO2004014345A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation |
| 02/19/2004 | WO2004014343A1 Storage stable tablets of fosinopril sodium |
| 02/19/2004 | WO2004014341A1 Oral injectable pharmaceutical composition comprising florfenicol as an active ingredient |
| 02/19/2004 | WO2004014340A1 Injectable composition comprising florfenicol as an active ingredient |
| 02/19/2004 | WO2004014339A1 Injectable composition comprising ceftiofur sodium as an active ingredient |
| 02/19/2004 | WO2004014337A2 A process for the preparation of dispersible tablet of cephalexin |
| 02/19/2004 | WO2004014336A2 Opioid-receptor antagonists in transdermal systems having buprenorphine |
| 02/19/2004 | WO2004014335A2 Dual-spike release formulation for oral drug delivery |
| 02/19/2004 | WO2004014322A2 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 02/19/2004 | WO2004014320A2 Methods of using beta glucan as a radioprotective agent |
| 02/19/2004 | WO2004014318A2 Levothyroxine compositions and methods |
| 02/19/2004 | WO2004014317A2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |